Written by Dr. Roupen Odabashian MD, FRCPC
Medical Oncologist, BC Cancer Abbotsford | Founder, MeDucation AI | Updated November 2026
The verdict: if you're due for ABIM Hematology or Medical Oncology recertification in 2026, take the Longitudinal Knowledge Assessment (LKA), not the traditional 10-year exam — and if you subspecialize heavily in breast cancer or hematologic neoplasms, switch into the new focused LKA tracks that launched this year while the one-time switch window is open. The data backs this up: physicians choosing an assessment pick the LKA over the traditional exam by roughly four to one[1], and in medical oncology specifically, nearly 85% of those due for assessment in 2026 chose the LKA over the 10-year exam[2]. The traditional exam still exists, is still open-book with UpToDate access[3][4], and is still the right call for a narrow group of attendings — mainly those who strongly prefer one long study push over a five-year grind of quarterly questions.
Conflict of interest, up front: I'm a practicing medical oncologist at BC Cancer Abbotsford and I founded MeDucation AI, which sells a physician-written heme/onc question bank and other board-prep and CME tools. Nothing here is written to sell you that product. Where BoardVitals, ASCO-SEP, or ASH-SAP are the better fit for recertification specifically, I'll say so.
Which recertification path should you actually pick in 2026?
For nearly all practicing hematologists and oncologists, the LKA beats the traditional MOC exam on time, stress, and how closely it matches daily practice. Here's the ranked comparison before the detail.
Rank | Option | Best for | Key trade-off |
|---|---|---|---|
1 | LKA (focused track if eligible) | Attendings who subspecialize and want low-stress, spread-out assessment | Five-year commitment, quarterly cadence[1][5] |
2 | LKA (general track) | Attendings with broad practice scope, not ready to commit to a focus area | Same blueprint weighting as the traditional exam[5] |
3 | Traditional 10-year MOC exam | Attendings who prefer one concentrated study block over recurring quarterly questions | Single high-stakes day, 220 questions[3][4] |
4 | Letting certification lapse, then using LKA to regain it | Nobody by design — only relevant after a lapse has already happened | LKA can be used to regain a lapsed certification after a five-year cycle[5][2] |
What actually changed for the Medical Oncology LKA in 2026?
ABIM announced it would "develop two new assessment options for oncologists: a version of the Medical Oncology Longitudinal Knowledge Assessment (LKA®) that focuses on breast cancer and another that focuses on hematologic neoplasms," with "launch of these new LKAs" set for "July 2026"[6]. By the ABIM Winter 2026 update, both had gone live: "Medical Oncology LKA with Breast Cancer Focus and Medical Oncology LKA with Hematologic Neoplasms Focus"[5] were listed among the five new focused assessments that actually launched. The Hematology LKA split similarly, into "Malignant Focus and Hematology LKA with Classical (Non-Malignant) Focus"[5], which had targeted a January 2026 launch[1] and also shipped on schedule.
If you were already enrolled in the general Hematology or Medical Oncology LKA, you had a one-time option to switch: "Physicians currently participating in the general Hematology, Gastroenterology or Medical Oncology LKAs may choose to switch to one of the new focused assessments with no impact to their current five-year cycle, but only this year"[5]. Switching doesn't change what your certificate says — "your certification will continue to be listed under the broader discipline (Hematology, Gastroenterology or Medical Oncology) rather than a specific focus area"[2] — it only changes the mix of questions you receive. The practical reason ABIM built these tracks: "we've heard feedback from the community that this assessment doesn't always align with what they see in practice, especially those who choose to subspecialize"[6], and ABIM used "physician surveys and Medicare claims" to set the new content distribution[6].
What does the Hematologic Neoplasms focus actually test?
Heavier on malignant heme content, lighter on everything else, relative to the general Medical Oncology blueprint. The published content outline for the Hematologic Neoplasms Focus LKA, effective "beginning with the 2026 Quarter 3 Hematologic Neoplasms Focus Longitudinal Knowledge Assessment"[7], breaks down as follows.
Content category | Target % of questions |
|---|---|
Hematologic Neoplasms | 42.5%[7] |
Gastrointestinal Cancer | 8.5%[7] |
Breast Cancer | 8.5%[7] |
Palliative Care, Survivorship, and Communication | 7.5%[7] |
Genitourinary Cancer | 7.5%[7] |
Thoracic Cancer | 7%[7] |
Clinical Research Methodology and Ethics | 6.5%[7] |
Gynecologic Cancer | 4%[7] |
Skin Cancer, Sarcomas, and Unknown Primary Site | 4%[7] |
Head, Neck, Thyroid, and CNS Malignancies | 4%[7] |
Compare that to 14% for Hematologic Neoplasms on the general Medical Oncology blueprint[3] — the focused version roughly triples the weight on malignant heme content while compressing solid-tumor categories. By task, the Hematologic Neoplasms LKA weights "Treatment/Care Decisions" at 60%, "Diagnosis/Testing" at 25%, "Risk Assessment/Prognosis/Epidemiology" at 10%, and "Pathophysiology/Basic Science" at 5%[7]. If your practice is heavily malignant hematology, this track tests closer to what you actually do. ABIM is explicit that "the focused assessments cover the same topics as the general specialty blueprint with a greater proportion of questions in the area of focus," built "for physicians who practice primarily in one subspecialty area"[5].
